Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Characterizing sexuality and assessing predictors of sexual satisfaction in patients with multiple myeloma and other hematological cancers.
Support Care Cancer
January 2025
Department of Psychology, University of Calgary, Calgary, AB, Canada.
Purpose: Existing studies documenting cancer-related sexual concerns among hematological cancer patients tend to group all types of hematological cancer together, overlooking potentially unique concerns associated with multiple myeloma (MM). This study is the first to characterize sexuality in MM and to examine predictors of sexual satisfaction for MM, comparatively with participants with other hematological cancer types.
Methods: We conducted a cross-sectional self-report survey-based study.
Outcomes of Older Adults and Frail Patients Receiving Idecabtagene Vicleucel: A CIBMTR Study.
Blood Adv
December 2024
H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of CAR T in older adults and frail patients with RRMM. In this study, we utilized data from the Center for International Blood and Marrow Transplantation Registry to describe the safety and efficacy of ide-cel in these clinically important subgroups.
View Article and Find Full Text PDFTargeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma.
Blood
December 2024
Central South University, Changsha, China.
Multiple myeloma (MM)-induced bone disease affects not only patients' quality of life but also their overall survival. Our previous work demonstrated that the gut microbiome plays a crucial role in MM progression and drug resistance. However, the role of altered gut microbiota in MM bone disease remains unclear.
View Article and Find Full Text PDFEvaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.
Am J Hematol
January 2025
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
This meta-analysis examined the association between minimal residual disease (MRD) negativity and survival outcomes in 15 304 patients with multiple myeloma (MM) enrolled in randomized controlled trials published until June 2, 2024. Overall, there was a significant, negative and strong association between MRD negativity odds ratios and survival hazard ratios (β_PFS = -0.20, p < 0.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.
Aims: The Alzheimer Association (AA) has proposed new diagnostic criteria for Alzheimer's disease (AD) based on biomarkers coinciding with β-amyloidosis onset. However, there are concerns regarding the implications of these criteria.
Methods: We reviewed several perspectives, including disease definition, public health, philosophy, therapeutic, and diagnostic.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!